Conclusion:

Tocilizumab administration in subjects with severe COVID-19 infection reduced the mortality rate in all time points, however, the incidence of adverse effect was higher. Therefore, patients with severe COVID-19 specially those with hyperinflammation may benefit from tocilizumab use taking into consideration the adverse effects of the biological drug. However, the limitations of the study would encourage researchers to conduct further investigations with randomized clinical trials.
Ethics Statement: The authors confirm that the ethical policies of the journal, as noted on the journal’s author guidelines page, have been adhered to. No ethical approval was required as this is a review article with no original research data